Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Xeris Biopharma Holdings, Inc. (XERS) had Cost of Goods Sold of $12.51M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$92.10M |
|
$-31.10M |
|
|
Cost of Goods Sold |
$12.51M |
$79.59M |
|
$86.93M |
|
$5.17M |
|
$-36.27M |
|
$-31.10M |
|
$-31.10M |
|
$-31.10M |
|
$-31.10M |
|
$-31.10M |
|
$-31.10M |
|
$5.17M |
|
$9.29M |
|
172.82M |
|
172.82M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$274.76M |
|
$4.83M |
|
$137.15M |
|
$411.90M |
|
$189.57M |
|
$188.81M |
|
$232.07M |
|
$421.64M |
|
$-9.73M |
|
$-115.25M |
|
$-9.73M |
|
173.59M |
|
| Cash Flow Statement Financials | |
$18.13M |
|
$-0.53M |
|
$-6.89M |
|
$115.06M |
|
$125.77M |
|
$10.71M |
|
$15.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.45 |
|
-- |
|
-- |
|
1.05 |
|
-25.95 |
|
86.41% |
|
5.62% |
|
5.62% |
|
-- |
|
-33.77% |
|
-33.77% |
|
$17.60M |
|
-- |
|
-- |
|
-- |
|
0.22 |
|
0.15 |
|
1.59 |
|
56.78 |
|
319.51% |
|
26.99% |
|
-7.55% |
|
-17.37% |
|
$-0.06 |
|
$0.10 |
|
$0.10 |
|